Risk prediction algorithms in guiding antiviral therapy initiation among patients with chronic hepatitis B in Thailand: an economic evaluation and budget impact analysis

References

• Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–1691. doi: 10.1001/jamaoncol.2017.3055
   PubMed Web of Science ®Google Scholar
• Razavi-Shearer D, Gamkrelidze I, Nguyen MH. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403. doi: 10.1016/S2468-1253(18)30056-6
   PubMed Web of Science ®Google Scholar
• Hutin Y, Nasrullah M, Easterbrook P, et al. Access to treatment for hepatitis B virus infection - worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(28):773–777. doi: 10.15585/mmwr.mm6728a2
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: aASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi: 10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T, et al. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi: 10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Thai Association for the Study of the Liver (THASL). Thailand practice guideline for management of chronic hepatitis B and C 2015. In: Thongsawat S, editors. Thai Association for the Study of the Liver (THASL). Bangkok: Thailand: Parbpim, Ltd Part; 2015. p. 4–12.
   Google Scholar
• Tian F, Houle SKD, Alsabbagh MW, et al. Cost-effectiveness of tenofovir alafenamide for treatment of chronic hepatitis B in Canada. Pharmacoeconomics. 2020;38(2):181–192. doi: 10.1007/s40273-019-00852-y
   PubMed Web of Science ®Google Scholar
• Varbobitis I, Papatheodoridis GV. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol. 2016;22(3):319–326. doi: 10.3350/cmh.2016.0045
   PubMed Web of Science ®Google Scholar
• Huang ZH, Lu GY, Qiu LX, et al. Risk of hepatocellular carcinoma in antiviral treatment-naive chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. BMC Cancer. 2022;22(1):287. doi: 10.1186/s12885-022-09413-7
   PubMed Web of Science ®Google Scholar
• Tan DJH, Ng CH, Tay PWL, et al. Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis. JAMA Netw Open. 2022;5(6):e2219407. doi: 10.1001/jamanetworkopen.2022.19407
   PubMed Web of Science ®Google Scholar
• Voulgaris T, Papatheodoridi M, Lampertico P, et al. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int. 2020;40(3):484–495. doi: 10.1111/liv.14334
   PubMed Web of Science ®Google Scholar
• Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50(1):80–88. doi: 10.1016/j.jhep.2008.07.023
   PubMed Web of Science ®Google Scholar
• Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28(10):1660–1665. doi: 10.1200/JCO.2009.26.2675
   PubMed Web of Science ®Google Scholar
• Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12(6):568–574. doi: 10.1016/S1470-2045(11)70077-8
   PubMed Web of Science ®Google Scholar
• Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800–806. doi: 10.1016/j.jhep.2015.11.035
   PubMed Web of Science ®Google Scholar
• Shimakawa Y, Njie R, Ndow G, et al. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. J Hepatol. 2018;69(4):776–784. doi: 10.1016/j.jhep.2018.05.024
   PubMed Web of Science ®Google Scholar
• Thanapirom K, Suksawatamnuay S, Thaimai P, et al. Assessment and validation of the TREAT-B score to assess the treatment eligibility of patients with chronic hepatitis B virus infection. Front Med. 2022;9:995857. doi: 10.3389/fmed.2022.995857
   Web of Science ®Google Scholar
• Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726–736. doi: 10.1002/hep.24105
   PubMed Web of Science ®Google Scholar
• Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196–206. doi: 10.1016/S2468-1253(16)30107-8
   PubMed Web of Science ®Google Scholar
• Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185–195. doi: 10.1016/S2468-1253(16)30024-3
   PubMed Web of Science ®Google Scholar
• Dilokthornsakul P, Sawangjit R, Tangkijvanich P, et al. Economic evaluation of oral nucleos(t)ide analogues for patients with chronic hepatitis B in Thailand. Appl Health Econ Health Policy. 2022;20(4):587–596. doi: 10.1007/s40258-022-00719-y
   PubMed Web of Science ®Google Scholar
• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–2166. doi: 10.1111/liv.12818
   PubMed Web of Science ®Google Scholar
• Geeratragool T, Tangkijvanich P, Nimanong S, et al. A novel and simplified score for determining treatment eligibility for patients with chronic hepatitis B. Viruses. 2023;15(3):724. doi: 10.3390/v15030724
   PubMed Web of Science ®Google Scholar
• Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–352. doi: 10.1016/j.jhep.2007.11.011
   PubMed Web of Science ®Google Scholar
• Ungtrakul T, Mahidol C, Chun-On P, et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World J Gastroenterol. 2016;22(34):7806–7812. doi: 10.3748/wjg.v22.i34.7806
   PubMed Web of Science ®Google Scholar
• Chongmelaxme B, Phisalprapa P, Sawangjit R, et al. Weight reduction and pioglitazone are cost-effective for the treatment of non-alcoholic fatty liver disease in Thailand. Pharmacoeconomics. 2019;37(2):267–278. doi: 10.1007/s40273-018-0736-0
   PubMed Web of Science ®Google Scholar
• Wongphan T, Bundhamcharoen K. Health-related quality of life as measured by EQ-5D and TFLIC-2 in liver cancer patients. Siriraj Med J. 2018;70:406–412.
   Google Scholar
• Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008;11(3):527–538. doi: 10.1111/j.1524-4733.2007.00297.x
   PubMed Web of Science ®Google Scholar
• Chaikledkaew U, Teerawattananon Y, Kongphitayachai S, et al. Guidelines for health technology assessment in Thailand. Nontahburi: Thailand: The graphico system; 2009.
   Google Scholar
• Chaikledkaew U, Teerawattananon Y. Guidelines for health technology assessment in Thailand. Nontahburi: Thailand: Wacharin; 2013.
   Google Scholar
• Riewpaiboon A. Standard cost list for health technology assessment (in Thai language). Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health. Nontahburi: Thailand; 2009. https://www.hitap.net/en/research/17640
   Google Scholar
• Pachanee K, Wongphan T, Prakongsai P. Economic evaluation and budget impact analysis of liver transplantation among Thai adults in universal health insurance coverage in Thailand. J Health Sci. 2016;25(5):908–919.
   Google Scholar
• Thongsawat S, Piratvisuth T, Pramoolsinsap C, et al. Resource utilization and direct medical costs of chronic hepatitis C in Thailand: a heavy but manageable economic burden. Value Health Reg Issues. 2014;3:12–18. doi: 10.1016/j.vhri.2013.09.002
   PubMedGoogle Scholar
• Sangmala P, Chaikledkaew U, Tanwandee T, et al. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients. Asian Pac J Cancer Prev. 2014;15(20):8993–9004. doi: 10.7314/APJCP.2014.15.20.8993
   PubMedGoogle Scholar
• Drug and medical supply information center: ministry of public health. median price for medications. Ministry of Public Health. 2022. Nonthaburi: Thailand. http://dmsic.moph.go.th/
   Google Scholar
• Bureau of Trade and Economic Indicies; Ministry of Commerce. Consumer price index. Ministry of Commerce. Nonthaburi: Thailand; 2021. http://www.price.moc.go.th/price/cpi/index_new_all.asp
   Google Scholar
• Exchange Rates UK. Thai Baht to US Dollar Spot Exchange Rates for 2021. 2021.
   Google Scholar
• Permsuwan U, Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. J Med Assoc Thai. 2014;97(Suppl 5):S50–58.
   PubMedGoogle Scholar
• The National Statistical Office. Number of population from registration by age, sex, region, and province. (Ed.^(eds). Bangkok: Thailand: The National Statistical Office; 2021.
   Google Scholar
• Leroi C, Adam P, Khamduang W, et al. Prevalence of chronic hepatitis B virus infection in Thailand: a systematic review and meta-analysis. Int J Infect Dis. 2016;51:36–43. doi: 10.1016/j.ijid.2016.08.017
   PubMed Web of Science ®Google Scholar
• de Fraga RS, Van Vaisberg V, Mendes LCA, et al. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol. 2020;55(5):496–514. doi: 10.1007/s00535-020-01680-0
   PubMed Web of Science ®Google Scholar
• Tseng CH, Chen TH, Wu JL, et al. Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: a systematic review and meta-analysis. JHEP Rep. 2023;5(1):100617. doi: 10.1016/j.jhepr.2022.100617
   PubMedGoogle Scholar